Hormone replacement therapy: changes in frequency and type of prescription by Dutch GPs during the last decade of the millennium

被引:10
|
作者
Donker, GA [1 ]
Spreeuwenberg, P [1 ]
Bartelds, AIM [1 ]
van der Velden, K [1 ]
Foets, M [1 ]
机构
[1] NIVEL Dutch Sentinel Practice Network, NL-3500 BN Utrecht, Netherlands
关键词
general practice; hormone replacement therapy; menopause; osteoporosis; prevention;
D O I
10.1093/fampra/17.6.508
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Objective. The present study was conducted in order to determine the change of frequency and type of hormone replacement therapy (HRT) regimen newly prescribed by Dutch GPs. Methods. A comparison was made of two data sets (multi-stage random samples) collected in 1987/88 and from 1995 to 1998 concerning women 40 years and older who were newly prescribed HRT. Results. Compared with 1987/88, 50% more patients were newly prescribed HRT in 1998 (2.0 in 1987/88 and 3.0 in 1998 per 1000 registered women, P < 0.01). The age distribution remained about the same, with a peak between 50 and 54 years in each year of registration. Unopposed oestrogens (including plasters) were prescribed less frequently (1.3<parts per thousand> in 1987/88 versus 0.7 parts per thousand in 1998, P < 0.001), and combinations of oestrogen and progestogen more frequently in 1998 (0.2<parts per thousand> in 1987/88 versus 1.8 parts per thousand in 1998, Pt 0.01). Sequential therapy was prescribed slightly more frequently than continuous therapy (65% sequential therapy in 1995; 55% in 1998). The most frequent reason for starting HRT in 1995-1998 was climacteric symptoms (89-98%), followed by osteoporosis prevention (16-28%) and early menopause (13-25%). Rarely were preventive goals the only reason (6%) for prescribing HRT. Conclusions. The number of HRT prescriptions increased by 50% over the last decade of the millennium. The age distribution remained the same. There was a tendency to shift from prescribing unopposed oestrogens to combinations of oestrogens and progestogens. Alleviation of climacteric symptoms was the main reason for prescribing HRT throughout the registration period. Prescription of HRT for prevention of osteoporosis and/or cardiovascular disease has so far not been adopted on a large scale by Dutch GPs.
引用
收藏
页码:508 / 513
页数:6
相关论文
共 39 条
  • [31] Changes in serum thyroid hormones levels and their mechanisms during long-term growth hormone (GH) replacement therapy in GH deficient children
    Portes, ES
    Oliveira, JHA
    Maccagnan, P
    Abucham, J
    CLINICAL ENDOCRINOLOGY, 2000, 53 (02) : 183 - 189
  • [32] CHANGES IN INSULIN-LIKE GROWTH FACTOR-I AND GROWTH-HORMONE AND PREVENTION OF BONE LOSS DURING ESTROGEN REPLACEMENT THERAPY
    DUURSMA, SA
    JASZMANN, LJB
    DERAADT, ME
    VANRIJN, HJM
    WIT, JM
    RAYMAKERS, JA
    GROWTH REGULATION, 1992, 2 (03): : 101 - 107
  • [33] Association Between Vitamin D and Carboxy-Terminal Cross-Linked Telopeptide of Type I Collagen in Children During Growth Hormone Replacement Therapy
    Witkowska-Sedek, Ewelina
    Stelmaszczyk-Emmel, Anna
    Kucharska, Anna
    Demkow, Urszula
    Pyrzak, Beata
    CLINICAL INVESTIGATION, 2018, 1047 : 53 - 60
  • [34] Type and location of thromboembolism in females carrying FV Leiden mutation during pregnancy/puerperium or oral contraceptive/hormone replacement therapy: experience from a single center
    Spyrou, A.
    Papadakis, E.
    Mpanti, A.
    Loukidhs, K.
    Efraimidou, S.
    Tsimirika, K.
    Gatsa, E.
    Karagianni, A.
    Georgiou, E.
    Kioumi, A.
    Korantzis, I.
    THROMBOSIS RESEARCH, 2011, 127 : S145 - S145
  • [35] Bone mineral density changes during an 18 month observational period following discontinuation of recombinant human parathyroid hormone (1-34) treatment of postmenopausal women receiving hormone replacement therapy.
    Ste-Marie, LG
    Scheele, WH
    Jasqui-Romano, S
    Schwartz, SL
    Clancy, AD
    Myers, SL
    ARTHRITIS AND RHEUMATISM, 2001, 44 (09): : S257 - S257
  • [36] Significance of serum CrossLaps as a predictor of changes in bone mineral density during estrogen replacement therapy; comparison with serum carboxyterminal telopeptide of type I collagen and urinary deoxypyridinoline
    Okabe, R
    Inaba, M
    Nakatsuka, K
    Miki, T
    Naka, H
    Moriguchi, A
    Nishizawa, Y
    JOURNAL OF BONE AND MINERAL METABOLISM, 2004, 22 (02) : 127 - 131
  • [37] Significance of serum CrossLaps as a predictor of changes in bone mineral density during estrogen replacement therapy; comparison with serum carboxyterminal telopeptide of type I collagen and urinary deoxypyridinoline
    Reiko Okabe
    Masaaki Inaba
    Kiyoshi Nakatsuka
    Takami Miki
    Hiroshi Naka
    Atushi Moriguchi
    Yoshiki Nishizawa
    Journal of Bone and Mineral Metabolism, 2004, 22 : 127 - 131
  • [38] Changes in skeletal muscle qualities during enzyme replacement therapy in late-onset type II glycogenosis: temporal and spatial pattern of mass vs. strength response
    Ravaglia, Sabrina
    Pichiecchio, Anna
    Ponzio, Michela
    Danesino, Cesare
    Garaghani, Kolsoum Saeidi
    Poloni, Guy Umberto
    Toscano, Antonio
    Moglia, Arrigo
    Carlucci, Annalisa
    Bini, Paola
    Ceroni, Mauro
    Bastianello, Stefano
    JOURNAL OF INHERITED METABOLIC DISEASE, 2010, 33 (06) : 737 - 745
  • [39] Time for a new, more inclusive endpoint for treatment of type 1 hepatorenal syndrome (HRS-1)? Small changes in serum creatinine (SCr) of &gt;20% are equivalent to HRS reversal (HRSR) in predicting survival and need for renal replacement therapy (RRT) during treatment of HRS-1 with terlipressin and albumin.
    Boyer, Thomas D.
    Wong, Florence
    Sanyal, Arun J.
    Pappas, Stephen Chris
    Jamil, Khurram
    HEPATOLOGY, 2016, 64 : 1030A - 1031A